* Says can produce vaccine 11 weeks from gene sequence
* Says adhered to current good-manufacturing practices
* Plans to produce more batches for human testing
* Shares up more than 20 pct in pre-market trade
Aug 5 Novavax Inc (NVAX.O) said it could
manufacture its vaccine candidate for the new strain of H1N1
influenza virus within 11 weeks of receiving the gene sequence
from the U.S. Centers for Disease Control, sending its shares
up more than 20 percent in trading before the bell.
Production of the vaccine was carried out at Novavax's new
facility in Rockville, Maryland, in accordance with current
good-manufacturing (GMP) practices laid down by health
regulators, the company said.
"Demonstration of our ability to construct and produce
GMP-quality influenza vaccine within 12 weeks under real
pandemic conditions is an important and successful test of our
VLP technology," Jim Robinson, vice president of manufacturing
and quality operations at Novavax, said in a statement.
The company's virus-like particle technology uses a mimic
or decoy of the virus to shorten the time to develop a vaccine
for a new viral strain.
Novavax has completed a Phase I/IIa clinical study with a
H5N1 influenza VLP vaccine candidate and is currently in
mid-stage trials with a VLP based seasonal flu vaccine
Shares of the company were up $1.07 in pre-market trade.
They closed at $4.63 Tuesday on Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Anthony